Add to ORKGDelafloxacin is a new fluoroquinolone antimicrobial approved for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) in adults using dosage regimens of 300 mg intravenously every 12 hours, 450 mg orally every 12 hours, or switching from intravenous to oral regimens for a 5- to 14-day treatment duration. Dosage adjustments in patients with severe renal dysfunction (estimated glomerular filtration rate [eGFR] = 15-29 ml/min/1.73
Background: Acute bacterial skin and skin structure infections (ABSSSI) cause significant morbidity ...
The fluoroquinolone class of antimicrobials has been in clinical use for over 13 years. During that ...
The clinical and economic burden of community-acquired bacterial pneumonia (CABP) is significant and...
The emergence of antimicrobial resistance threatens current clinical practice across a range of infe...
Fluoroquinolones have been in clinical use for over 50 years with significant efficacy. However, inc...
The increase in hospitalization due to acute bacterial skin and skin structure infections (ABSSSI) c...
Francisco Javier Candel, Marina Peñuelas Department of Clinical Microbiology and Infectious ...
Introduction: There has been a striking increase in the emergence of multidrug-resistant pathogens i...
Elda Righi, Alessia Carnelutti, Antonio Vena, Matteo Bassetti Infectious Diseases Div...
Delafloxacin (formerly WQ-3034, ABT492, RX-3341) is a novel fluoroquinolone chemically distinct from...
Antibiotics (from ancient Greek αντιβιοτικά, antiviotika), also called antibacterials, are a type of...
Introduction: In the era of multi-drug resistant pathogens, the adequate treatment of skin and skin ...
SummaryBackgroundA randomized, double-blind, multicenter trial was done to compare two doses of dela...
Background Through improved understanding of the structure-activity relationship attributes of fluor...
www.theannals.com The emergence of antibiotic-resistant pathogens has cre-ated an impetus for the de...
Background: Acute bacterial skin and skin structure infections (ABSSSI) cause significant morbidity ...
The fluoroquinolone class of antimicrobials has been in clinical use for over 13 years. During that ...
The clinical and economic burden of community-acquired bacterial pneumonia (CABP) is significant and...
The emergence of antimicrobial resistance threatens current clinical practice across a range of infe...
Fluoroquinolones have been in clinical use for over 50 years with significant efficacy. However, inc...
The increase in hospitalization due to acute bacterial skin and skin structure infections (ABSSSI) c...
Francisco Javier Candel, Marina Peñuelas Department of Clinical Microbiology and Infectious ...
Introduction: There has been a striking increase in the emergence of multidrug-resistant pathogens i...
Elda Righi, Alessia Carnelutti, Antonio Vena, Matteo Bassetti Infectious Diseases Div...
Delafloxacin (formerly WQ-3034, ABT492, RX-3341) is a novel fluoroquinolone chemically distinct from...
Antibiotics (from ancient Greek αντιβιοτικά, antiviotika), also called antibacterials, are a type of...
Introduction: In the era of multi-drug resistant pathogens, the adequate treatment of skin and skin ...
SummaryBackgroundA randomized, double-blind, multicenter trial was done to compare two doses of dela...
Background Through improved understanding of the structure-activity relationship attributes of fluor...
www.theannals.com The emergence of antibiotic-resistant pathogens has cre-ated an impetus for the de...
Background: Acute bacterial skin and skin structure infections (ABSSSI) cause significant morbidity ...
The fluoroquinolone class of antimicrobials has been in clinical use for over 13 years. During that ...
The clinical and economic burden of community-acquired bacterial pneumonia (CABP) is significant and...